AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
183.26
+0.72 (0.39%)
At close: May 23, 2025, 4:00 PM
183.25
-0.01 (-0.01%)
After-hours: May 23, 2025, 7:58 PM EDT
AbbVie Revenue
AbbVie had revenue of $13.34B in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
5.65
Revenue / Employee
$1,043,036
Employees
55,000
Market Cap
323.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
ABBV News
- 5 days ago - 69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs - Seeking Alpha
- 9 days ago - 3 Stocks That Will Profit From Trump's Drug Price Cut - Benzinga
- 9 days ago - Is It Time To Buy AbbVie Stock At $180? - Forbes
- 10 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV - PRNewsWire
- 11 days ago - Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer - Seeking Alpha
- 11 days ago - AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 11 days ago - US FDA approves AbbVie's drug for a type of lung cancer - Reuters
- 11 days ago - U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression - PRNewsWire